RORC and Foxp3 axis in cerebrospinal fluid of patients with Neuro-Behçet's Disease

Journal of Neuroimmunology

Volumn 233, Issue 1-2, 2011, Pages 249-253

  Hamzaoui, Kamel ^a   Borhani Haghighi, Afshin ^b   Ghorbel, Imed Ben ^c   Houman, Habib ^c  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LA RABTA HOSPITAL   (Tunisia)

Author keywords

FOXP3; Neuro Beh et's Disease; RORC; Transcription factors

Indexed keywords

COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MESSENGER RNA; PREDNISOLONE; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EBI3; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; MALE; NEURO BEHCET DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL;

ADULT; BEHCET SYNDROME; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 79953297480     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.01.012     Document Type: Article

References (42)

1. Akman-Demir G., Tüzün E., i̇çöz S., Yeşilot N., Sibel P., Yentür Kürtüncü M., Mutlu M., Saruhan-Direskeneli G. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine 2008, 44:373-376.
2. Al-Arij A., Kidd D.P. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009, 8:192-204.
3. Ayyoub M., Deknuydt F., Raimbaud I., Dousset C., Leveque L., Bioley G., Valmori D. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc. Natl Acad. Sci. USA 2009, 106:8635-8640.
4. Bilginer Y., Ayaz N.A., Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin. Rheumatol. 2010, 29:209-210.
5. Borhani Haghighi A. Comment on "histopathology of central nervous system lesions in Behcet's disease". J. Neurol. Sci. 2008, 270:211.
6. Borhani Haghighi A. Treatment of Neuro-Behçet's disease: an update. Exp. Rev. Neurother. 2009, 9:565-574.
7. Borhani Haghighi A., Ittehadi H., Nikseresht A.R., Rahmati J., Poorjahromi S.G., Pourabbas B., Nazarinia M.A., Habibagahi Z., Fattahi M.J., Ghaderi A. CSF levels of cytokines in neuro-Behçet's disease. Clin. Neurol. Neurosurg. 2009, 111:507-510.
8. Cañete J.D., Celis R., Noordenbos T., Moll C., Gómez-Puerta J.A., Pizcueta P., Palacin A., Tak P.P., Sanmartí R., Baeten D. Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Res. Ther. 2009, 11:R17.
9. Chi W., Yang P., Zhu X., Wang Y., Chen L., Huang X., Liu X. Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. Mol. Vis. 2010, 16:880-886.
10. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J. Immunol. 2009, 182:6121-6128.
11. Curtis M.M., Way S.S. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009, 126:177-185.
12. Dalghous A.M., Freysdottir J., Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand. J. Rheumatol. 2006, 35:472-475.
13. Deknuydt F., Bioley G., Valmori D., Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin. Immunol. 2009, 131:298-307.
14. Drulovic J., Savic E., Pekmezovic T., Mesaros S., Stojsavljevic N., Dujmovic-Basuroski I., Kostic J., Vasic V., Mostarica Stojkovic M., Popadic D. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?. J. Neuroimmunol. 2009, 2009(215):90-95.
15. Durmazlar S.P., Ulkar G.B., Eskioglu F., Tatlican S., Mert A., Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int. J. Dermatol. 2009, 48:259-264.
16. Edström M., Mellergård J., Mjösberg J., Jenmalm M.C., Vrethem M., Press R.C., Dahle C., Ernerudh J. Transcriptional characteristics of CD4+ T cells in multiple Transcriptional characteristics of CD4+ T cells in multiple sclerosis: relative lack of suppressive population in blood. Mult. Scler. 2010, 16:1-10.
17. Ekinci N.S., Alpsoy E., Karakas A.A., Yilmaz S.B., Yegin O. IL-17A has an important role in the acute attacks of Behçet's disease. J. Invest. Dermatol. 2010, 130:2136-2138.
18. Evans H.G., Suddason T., Jackson I., Taams L.S., Lord G.M. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc. Natl Acad. Sci. USA 2007, 104:17034-17039.
19. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
20. Hamzaoui K., Hamzaoui A., Guemira F., Bessioud M., Hamza M., Ayed K. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand. J. Rheumatol. 2002, 31:205-210.
21. Hamzaoui K., Kamoun M., Houman H., Hentati F., Hamza M., Ayed K., Hamzaoui A. Discrepancies of NKT cells expression in peripheral blood and in cerebrospinal fluid from Behçet's disease. J. Neuroimmunol. 2006, 175:160-168.
22. Hamzaoui K., Houman H., Hamzaoui A. Regulatory T cells in cerebrospinal fluid from Behçet's disease with neurological manifestations. J. Neuroimmunol. 2007, 187:201-204.
23. Hamzaoui K., Maître B., Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease. Clin. Exp. Rheumatol. 2009, 27:S52-S57.
24. Hamzaoui K., Ayed K., Hamza M., Hamzaoui A. VEGF and mRNA VEGF expression in CSF from Behçet's disease with neurological involvement. J. Neuroimmunol. 2009, 213:148-153.
25. Headache classification subcommittee of the international headache society The international classification of headache disorders, second edition. Cephalgia 2004, 24:1-160.
26. Hirohata S., Isshi K., Oguchi H., Ohse T., Haraoka H., Takeuchi A., Hashimoto T. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet's syndrome. Clin. Immunol. Immunopathol. 1997, 82:12-17.
27. Houman H., Ben Ghorbel I., Braham-Sfaxi A., Khanfir M., Ben Ahmed M., Lamloum M., Miled M. Risk factors of neuro-Behçet. Adv. Exp. Med. Biol. 2003, 528:143-146.
28. International Study Group for Behçet's Disease Criteria for diagnosis of Behçet's disease. Lancet 1990, 335:78-80.
29. Kao C.Y., Chen Y., Thai P., Wachi S., Huang F., Kim C., Richart Harper W., Wu R. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NFkappaB signaling pathways. J. Immunol. 2004, 173:3482-3491.
30. Kim J., Park J.A., Lee E.Y., Lee Y.J., Song Y.W., Lee E.B. Imbalance of Th17 to Th1 cells in Behçet's disease. Clin. Exp. Rheumatol. 2010, 20:S16-S19.
31. Kötter I., Koch S., Vonthein R., Rückwaldt U., Amberger M., Günaydin I., Zierhut M., Stübiger N. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin. Exp. Rheumatol. 2005, 23:S20-S26.
32. Niino M., Ogata A., Kikuchi S., Tashiro K., Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet's disease. J. Neurol. Sci. 2000, 179:127-131.
33. Ouyang W., Ranganath S.H., Weindel K., Bhattacharya D., Murphy T.L., Sha W.C., et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998, 9:745-755.
34. Saruhan-Direskeneli G., Yentür S.P., Akman-Demir G., Ii̇ik N., Serdarocǧlu P. Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. J. Neuroimmunol. 2003, 145:127-134.
35. + T cells. Immunogenetics 2000, 51:771-778.
36. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 2008, 14:337-342.
37. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
38. Usui Y., Takeuchi M., Yamakawa N., Takeuchi A., Kezuka T., Ma J., Matsuda R., Okunuki Y., Akiba H., Goto H. Expression and function of inducible costimulator on peripheral blood CD4+ T cells in Behçet's patients with uveitis: a new activity marker?. Invest. Ophthalmol. Vis. Sci. 2010, 51:5099-5104.
39. Williams L.M., Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 2007, 8:277-284.
40. Yang J., Yang M., Htut T.M., Ouyang X., Hanidu A., Li X., Sellati R., Huiping Jiang H., Shu Zhang S., Li H., Zhao J., Ting A.J., Mayer L., Unkeless J.C., Labadia Mark E., Hodge M., Li J., Huabao Xiong H. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and ROR gamma t. Eur. J. Immunol. 2008, 38:1204-1214.
41. Zheng W., Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587-596.
42. Zhou L., Lopes J.E., Mark M.W., Chong Ivaylo, Ivanov I., Min Roy, Victora Gabriel D., Shen Yuelei, Jianguang Du., Rubtsov Y.P., Rudensky Alexander Y., Ziegler S.F., Littman Dan R. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.